904326-93-8

Basic information

• Product Name: 6-(4-morpholinyl)-3-pyridinylboronic acid
• Synonyms: 2-MORPHOLINO-5-PYRIDINEBORONIC ACID;2-MORPHOLINOPYRIDINE-5-BORONIC ACID;[6-(4-MORPHOLINYL)-3-PYRIDINYL]BORONIC ACID;6-MORPHOLINOPYRIDINE-3-BORONIC ACID;6-(4-MORPHOLINYL)-3-PYRIDINEBORONIC ACID;6-morpholin-4-yl-pyridineboronic acid;6-morpholinopyridin-3-yl-3-boronic acid;6-morpholinopyridin-3-ylboronic acid
• CAS NO: 904326-93-8
• Molecular Formula: C₉H₁₃BN₂O₃
• Molecular Weight: 208.02
• Product Categories: Boronate Ester;Boronic Acid;Potassium Trifluoroborate
• Mol File: 904326-93-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 458.6 °C at 760 mmHg
• Flash Point: 231.2 °C
• Appearance: /
• Density: 1.3 g/cm³
• Vapor Pressure: 3.31E-09mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.68±0.18(Predicted)
• CAS DataBase Reference: 6-(4-morpholinyl)-3-pyridinylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-morpholinyl)-3-pyridinylboronic acid(904326-93-8)
• EPA Substance Registry System: 6-(4-morpholinyl)-3-pyridinylboronic acid(904326-93-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 904326-93-8(Hazardous Substances Data)

Usage

General Description

6-(4-morpholinyl)-3-pyridinylboronic acid is a chemical compound with a molecular formula C10H14BNO4. It is an organoboronic acid that contains a pyridine and a morpholine ring. 6-(4-morpholinyl)-3-pyridinylboronic acid is commonly used as a reagent in organic synthesis, especially in the formation of carbon-carbon and carbon-heteroatom bonds through cross-coupling reactions. It is also utilized in medicinal chemistry for the development of potential pharmaceuticals and bioactive molecules. Its boronic acid functionality enables it to form stable complexes with diols and other Lewis bases, making it useful in the design of sensors and diagnostic tools. Additionally, 6-(4-morpholinyl)-3-pyridinylboronic acid has been investigated for its anticancer and antitumor properties, showing potential as a targeted therapy agent.

InChI:InChI=1/C9H13BN2O3/c13-10(14)8-1-2-9(11-7-8)12-3-5-15-6-4-12/h1-2,7,13-14H,3-6H2

Upstream product

• 200064-11-5 5-bromo-2-(4-morpholinyl)pyridine 
• 73183-34-3 bis(pinacol)diborane 
• 13534-99-1 2-Amino-3-bromopyridine 

Downstream Products

• 1220690-30-1 N-(3-(cyclopentyloxy)-4-methoxybenzyl)-6'-morpholino-3,3'-bipyridin-5-amine 
• 24255-25-2 4-(pyridin-2-yl)morpholine 
• 26820-62-2 4-(5-nitro-pyridin-2-yl)-morpholine 
• 134787-63-6 4-(3,5-dinitropyridin-2-yl)morpholine 
• 24255-27-4 4-(3-nitropyridin-2-yl)morpholine 
• 1416981-84-4 4-(5-benzylpyridin-2-yl)morpholine 
• 1448536-60-4 N-(4-((6-morpholinopyridin-3-yl)sulfonyl)benzyl)acetamide 
• 1362134-22-2 C₂₃H₂₂N₆O₄S 
• 1448536-62-6 (4-((6-morpholinopyridin-3-yl)sulfonyl)-phenyl)methanamine 
• 1362753-40-9 2-cyano-1-({4-[6-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl}methyl)-3-(pyridin-4-yl)guanidine 
• 90648-77-4 6-morpholino-pyridine-3-sulfonic acid amide 
• 1222767-12-5 N-(5-methyl-1,2-oxazol-3-yl)-2-[1-({3-[6-(morpholin-4-yl)pyridin-3-yl]phenyl}methyl)-1H-indole-3-sulfonyl]acetamide 

Relevant articles and documents

Azaindole derivative myelocyte proliferation inhibitor, preparation method thereof, and application of inhibitor in pharmacy

The invention provides an azaindole derivative myeloid proliferation inhibitor as shown in a formula I. In the formula, R1, R2 and R33 are as defined in the specification. The compound shown in the formula I can be used for remarkably inhibiting the proliferation of myeloid cells represented by MOLM-16, HL-60 and MV-4-11 and related diseases of the myeloid cells. The compound shown in the formula I or the salt thereof or the related pharmaceutical composition provided by the invention has excellent in-vivo and in-vitro inhibitory activity, good druggability and high bioavailability, and does not have obvious injury to visceral organs. Therefore, the compound shown in the formula I or the salt thereof and the related pharmaceutical composition have huge clinical application prospects.

Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor δ agonists

The discovery, synthesis, and optimization of compound 1 from a high-throughput screening hit to highly potent and selective peroxisome proliferator-activated receptor δ (PPARδ) agonists are reported. The synthesis and structure-activity relationship in this series are described in detail. On the basis of a general schematic PPAR pharmacophore model, scaffold 1 was divided into headgroup, linker, and tailgroup and successively optimized for PPAR activation using in vitro PPAR transactivation assays. A (2-methylphenoxy)acetic acid headgroup, a flexible linker, and a five-membered heteroaromatic center ring with two hydrophobic aryl substituents were required for efficient and selective PPARδ activation. The fine-tuning of these aryl substituents led to an array of highly potent and selective compounds such as compound 38c, displaying an excellent pharmacokinetic profile in mouse. In an in vivo acute dosing model, selected members of this array were shown to induce the expression of pyruvate dehydrogenase kinase-4 (PDK4) and uncoupling protein-3 (UCP3), genes that are known to be involved in energy homeostasis and regulated by PPARδ in skeletal muscle.